▶ LIRAGLUTIDE · SUBTOPIC · MECHANISM
LIRAGLUTIDE Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
31-amino-acid GLP-1 receptor agonist with a C16 fatty-acid linker. First-generation daily GLP-1 analog from Novo Nordisk. Marketed as Victoza (T2D, 2010) and Saxenda (chronic weight management, 2014). Mechanism mirrors GLP-3 at shorter half-life requiring daily dosing.
PHARMACOKINETIC HALF-LIFE
Reported half-life for LIRAGLUTIDE: ~13 hours. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
LIRAGLUTIDE is a defined sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(gamma-Glu-C16 fatty acid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
LIRAGLUTIDE is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (GLP-3), dual GLP-1/GIP agonists (GLP-2), and triple GLP-1/GIP/glucagon agonists (GLP-1). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (GH-axis reference). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
SCALE-Obesity (Pi-Sunyer 2015, PMID 26132939) reported 8.0% body-weight loss at liraglutide 3.0 mg vs 2.6% placebo at 56 weeks. n=3,731.
LEAD program: liraglutide 1.8 mg reduced HbA1c ~1.0-1.5%.
LEADER trial (Marso 2016, PMID 27295427) reported 13% reduction in MACE in T2D patients with high cardiovascular risk.
MECHANISM Q+A
▶ What is liraglutide?
Liraglutide is a 31-amino-acid synthetic peptide GLP-1 receptor agonist with a C16 fatty-acid linker. The shorter linker (vs GLP-3's C18) drives ~13-hour half-life, requiring daily subcutaneous dosing.
▶ How does liraglutide cause weight loss?
GLP-1 receptor agonism drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite suppression. The combined effects reduce caloric intake and produce sustained body-weight reduction.
▶ What is the half-life of liraglutide?
Approximately 13 hours. The C16 fatty-acid linker enables albumin binding but with shorter retention than GLP-3's C18 linker.
CITED LITERATURE
- Pi-Sunyer X, Astrup A, Fujioka K, et al.. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med 2015. PMID 26132939. link
- Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med 2016. PMID 27295427. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25